Neuroone Med Technologies Corp Stock Price, News & Analysis

NeuroOne Medical Technologies (Nasdaq: NMTC), a medical technology company specializing in neurological disorder treatments, has announced its participation in The ThinkEquity Conference on October 30, 2024. The event will be held at the Mandarin Oriental Hotel in New York. CFO Ron McClurg will deliver a presentation at 9:00 am ET, and the company will conduct one-on-one investor meetings throughout the day. The conference brings together institutional investors, corporate clients, and industry professionals to showcase innovations and financial strategies. The presentation will be available via live stream, and interested investors can register to attend and schedule meetings.

NeuroOne Medical Technologies (Nasdaq: NMTC) announced that its percutaneous paddle technology for spinal cord stimulation will be featured at The Business of Pain Meeting in Nashville, TN. Dr. Sean Li, a renowned pain specialist and course director, will present on this innovative tool for lower back pain.

Dr. Li, President of the New Jersey Society of Interventional Pain Physicians and Treasurer of the American Society of Pain and Neuroscience, praised the technology as the most advanced percutaneous spinal cord stimulation electrode he has worked with. He believes it combines the benefits of surgically placed paddle electrodes with those of percutaneous placement, potentially improving treatment for chronic lower back pain patients.

NeuroOne estimates the current spinal cord stimulation market to be approximately $3 billion worldwide, citing large addressable patient populations with unmet clinical needs.

NeuroOne Medical Technologies (Nasdaq: NMTC) announced a breakthrough case using its OneRF™ Ablation System at University Hospitals in Cleveland. Forty-four ablations were successfully performed on one patient over two days, guided by sEEG recordings. The patient is reportedly seizure-free two months post-procedure, with improvements in mood and memory.

Dr. Michael Staudt, the lead neurosurgeon, expressed satisfaction with the system's performance and its potential to benefit many patients. CEO Dave Rosa highlighted the case's uniqueness, exceeding the range of ablations found in clinical literature. The OneRF™ Ablation System is NeuroOne's third FDA 510(k)-cleared device and first with a therapeutic indication. NeuroOne estimates the current brain ablation market at $100M worldwide with significant growth potential.

NeuroOne Medical Technologies (NMTC), a medical technology company focused on improving surgical care for neurological disorders, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place both in-person and virtually from September 9-11, 2024.

Chief Operating Officer Chris Volker will deliver a virtual presentation, available on demand starting at 7:00 a.m. ET on Monday, September 9, 2024, and continuing throughout the conference. Investors can register for the conference online to access the presentation. Additionally, registered investors can schedule one-on-one meetings through the conference website or by contacting their H.C. Wainwright representative.

NeuroOne Medical Technologies (NMTC) reported its Q3 fiscal year 2024 financial results and provided a corporate update. Key highlights include:

- Product revenue increased to $826,000 in Q3 2024, up from $630,000 in Q3 2023
- Operating expenses reduced from $3.8 million to $3.1 million year-over-year
- Completed first implants and ablations with OneRF™ Ablation System
- Signed non-binding term sheet for distribution partnership of OneRF™ Ablation System
- Raised $1.6 million through ATM Program in Q3 2024
- Completed $2.65 million private placement and secured $3.0 million credit facility in August 2024

The company continues to advance its product pipeline, including RF ablation applications, sEEG-based drug delivery, and a percutaneous paddle lead for spinal cord stimulation.

NeuroOne Medical Technologies (Nasdaq: NMTC), a medical technology company focused on improving surgical care options for neurological disorders, has announced it will host a conference call and webcast on August 14, 2024, at 4:30 PM Eastern Time. The event will cover financial results for the third quarter of fiscal year 2024 ended June 30, 2024, and provide a corporate update.

The conference call will be accessible via toll-free and international numbers, with a participant access code. A phone replay will be available until August 28, 2024. Additionally, a live webcast will be provided, with the replay available for 12 months.

NeuroOne Medical Technologies (Nasdaq: NMTC) has secured $5.65 million in financing through a combination of a $2.65 million private placement and a $3 million credit facility. The private placement involved issuing 2,944,446 shares of common stock and warrants to purchase 2,208,338 additional shares at $0.90 per unit. The company also announced signing a non-binding term sheet with an undisclosed global medical technology company for the distribution of its OneRF™ Ablation System.

The funds will be used for OneRF commercialization activities, product development for a new ablation indication, and to support the company during the diligence process with a potential strategic partner. CEO Dave Rosa expressed confidence in the company's position to operate and move forward with the potential partnership, expected to close by the end of the third calendar quarter.

NeuroOne Medical Technologies (Nasdaq: NMTC) announced the successful use of its OneRF Ablation System to perform five ablations on a patient with multifocal epilepsy at a prestigious hospital in Jacksonville, Florida. This was achieved using ten Evo sEEG electrodes, which identified seizure-triggering brain areas, and targeted ablations were confirmed by post-ablation sEEG recordings. The procedure was performed at the bedside, saving time and costs associated with operating room use. The OneRF Ablation System is NeuroOne’s first therapeutic device and third FDA 510(k)-cleared device. CEO Dave Rosa highlighted the system's potential to reduce operating room usage and foresees the expansion of its applications with future FDA submissions.

NeuroOne now offers a complete line of thin film electrode technology for diagnostic brain mapping and RF ablation. The estimated brain ablation market is over $100 million worldwide and is expected to grow significantly due to unmet clinical needs.

NeuroOne announced that the CMS has approved a new ICD-10-PCS code for its OneRF™ Ablation procedure, effective October 1, 2024. This code, 00503Z4, facilitates hospital reporting of inpatient procedures using the FDA-cleared OneRF™ Ablation system, aimed at creating RF lesions for neurosurgical operations. CEO Dave Rosa highlighted that this approval is key to increasing the recognition and utilization of their technology, potentially reducing hospital stays and adverse events. NeuroOne's product portfolio includes the Evo® cortical and sEEG electrode lines for brain mapping and RF ablation, with the brain ablation market estimated to exceed $100M globally.